OOIR: Observatory of International Research

Papers

(The H4-Index of Experimental Hematology & Oncology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Complex roles of cAMP–PKA–CREB signaling in cancer	196
CD44 as a tumor biomarker and therapeutic target	170
Leukemia incidence trends at the global, regional, and national level between 1990 and 2017	120
Risk factors and outcome of COVID-19 in patients with hematological malignancies	109
SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients	65
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC	63
Engineering better chimeric antigen receptor T cells	61
Research progress on dendritic cell vaccines in cancer immunotherapy	59
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017	57
Macrophage, the potential key mediator in CAR-T related CRS	53
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition	51
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies	50
Role of m6A writers, erasers and readers in cancer	48
MiRNA-mediated EMT and CSCs in cancer chemoresistance	46
Clinical implications of recurrent gene mutations in acute myeloid leukemia	45
Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma	44
Recent advances and challenges of bispecific antibodies in solid tumors	42
Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes	41
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder	40
Heterogeneity of the tumor immune microenvironment and its clinical relevance	38
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL	38
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment	35
COVID-19 vaccination associated severe immune thrombocytopenia	35
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients	35
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma	34

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development	33
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia	33
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy	31
Breast cancer heterogeneity and its implication in personalized precision therapy	31
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma	30